Abstract Body

Background:

The incidence of ischemic stroke in adults living with HIV (ALWH) is three times higher than healthy adults. Circulating endothelial cell-derived microvesicles (EMVs) have been linked to cerebrovascular events. We have previously reported that EMVs isolated from ALWH receiving antiretroviral therapy (ART) impair brain endothelial cell nitric oxide (NO) production and fibrinolytic capacity, central etiologic mechanisms in the pathogenesis of ischemic stroke. However, it is unknown whether the pathologic EMV phenotype is a consequence of HIV-1 per se or ART. The experimental aim of this study was to determine the effect of EMVs isolated from treatment naïve ALWH on brain endothelial cell nitric oxide NO production and fibrinolytic capacity.

Methods:

Circulating EMVs (CD 144-PE) were isolated (flow cytometry) from 16 young and middle-aged men (age range: 21-43 yr): 8 healthy (age 33±3 yr; BMI: 26.0±1.2 kg/m2; BP: 113/7±22/2 mmHg) and 8 treatment naïve ALWH (10M/2F; 36±2 yr; 25.3±1.5 kg/m2; BP: 117/76±3/3 mmHg; viral load: 5525 copies/mL). All men were free of overt cardiometabolic disease and not taking any medication. Human cerebral microvascular endothelial cells (hCMECs) were cultured and separately treated with EMVs from each subject.

Results:

Circulating EMVs were significantly higher in the treatment naïve ALWH (229±23 EMV/µL) compared with healthy adults (133±13 EMV/µL). Although total endothelial nitric oxide synthase (eNOS) expression was not significantly altered (60.1±2.3 vs 65.3±2.1 AU); active eNOS (pSer1177) (19.0±0.8 vs 26.6±1.5 AU) and, in turn, NO production (5.7±0.2 vs 6.7±0.3 µmol/L) was lower (P<0.05) in cells treated with EMVs from treatment naïve ALWH vs EMVs from healthy adults. HIV-associated EMVs also significantly reduced tissue-type plasminogen activator (t-PA) (25.5±1.2 vs 34.7±1.7 AU) and increased plasminogen activator inhibitor (PAI)-1 (146.0±4.5 vs 110.0± 3.8 AU) protein expression in hCMECs. The t-PA:PAI-1 intracellular protein ratio (5.9±0.3 vs 3.3±0.1 AU; P<0.05) was higher in HIV-1 EMV treated cells, indicative of decreased fibrinolytic capacity.

Conclusions:

HIV-1, independent of traditional risk factors and ART, is associated with a pathologic circulating EMV phenotype. Reduced NO bioavailability and impaired fibrinolytic capacity in brain endothelial cells heighten the risk and accelerated rate of ischemic stroke. EMVs represent a mechanistic factor underlying HIV-1-related cerebrovascular risk.